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A 72-year-old man who had suffered from rheumatoid arthritis (RA) and Sj€ogren's syndrome (Sjs) since
he was 66 years of age had been treated with methotrexate (MTX) for six years. He presented with a
cough, sputum and dyspnea on exertion, and computed tomography ﬁndings showed multiple ground-
glass opacities in both of his lungs. A biopsy of the lungs revealed low-grade mucosa-associated
lymphoid tissue (MALT) type B-cell non-Hodgkin's lymphoma. Spontaneous complete remission of the
lymphoma was achieved six months after withdrawing immune suppression with MTX. To our
knowledge, no previous cases of spontaneous regression of pulmonary MALT-type lymphoma with Sjs
treated with MTX for RA have been reported. Patients on MTX who are being treated for RA should be
carefully monitored, especially when they have been diagnosed with coexistent Sjs.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Several studies have suggested an increased risk of lymphoma in
patients with rheumatoid arthritis (RA). It has also been shown that
RA patients treated with methotrexate (MTX) can develop
lymphoproliferative disorders that share characteristics with lym-
phomas occurring in immunosuppressed patients. Similarly,
patients with Sj€ogren's syndrome (Sjs) also have a markedly
increased risk for developing non-Hodgkin's lymphoma (NHL),methotrexate; Sjs, Sj€ogren's
mucosa-associated lymphoid
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Ltd. This is an open access article uespecially with mucosa-associated lymphoid tissue (MALT)-type
lymphoma [1].
Herein, we describe a case of MALT-type lymphoma in a patient
with both RA and Sjs who had been treated with MTX. Interestingly
spontaneous remission of the lymphoma was achieved after
withdrawing MTX. The oncogenic potential of MTX in the setting of
both RA and Sjs is discussed.Case report
A 72 year-old man with a history of RA, Sjs, and nephrosclerosis
was referred to our institution with a cough, sputum, and dyspnea
on exertion. He had a smoking history of two packs of cigarettes/
day, but he had stopped smoking 20 years ago. He was treated with
MTX at a dose of 4 mg/week for six years for treatment of his RA.
Chest computed tomography (CT) showed multiple cysts with thin
wall, bilateral multiple ground-glass opacities, multiple nodules,
and interlobular septal thickening in the middle and lingular
segments (Fig. 1A). Serum and bronchoalveolar lavage ﬂuid (BAL)
testing for bacterial, viral, fungal, and mycobacterial infections
were negative. Therewere no atypical cells in the BAL ﬂuid. BAL cell
analysis revealed that a subset of lymphocytes was elevatednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest computed tomography (CT) scan revealed ground-glass opacities and interlobular septal thickening (A). Multiple ground-glass opacities and interlobular septal
thickening on CT showed spontaneous regression six months after the discontinuation of methotrexate (B).
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nant lymphocytic alveolitis (% CD4:CD8 ¼ 0.52). With a presump-
tive diagnosis of a MTX-related lung complication, MTX was
discontinued. To reach a deﬁnite diagnosis, video assisted thoracic
surgery was performed and samples were taken from S5 and S8 of
the right lung. Histopathological evaluation and immunohisto-
chemistry led to the diagnosis of an extranodal marginal zone
lymphoma of theMALT-type (Fig. 2). Nometastasis was detected by
bone marrow aspiration or CT scans evaluating from neck to pelvis,
and gastroscopy was negative. Interestingly, the multiple ground-
glass opacities and interlobular septal thickening that were
observed on CT images underwent spontaneous regression six
months after the discontinuation of MTX (Fig. 1B). To date, he re-
mains in complete remission, and his rheumatoid symptoms are
well controlled with non-steroidal anti-inﬂammatory drugs.
Discussion
Baecklund et al. reported that the risk of lymphoma is increased
in a subset of patients with very severe RA [2]. Elevated inﬂam-
matory activity is a major risk determinant; however, no causal link
has been established. MTX is commonly used as a disease-
modifying agent in patients with RA, in whom it interferes withFig. 2. The cellular inﬁltrate is present along the alveolar septa and the interlobular septu
magniﬁcation showing predominantly small lymphoid cells in the inﬁltrate (A). The immun
immunoglobulin l light chains (B).DNA synthesis, repair, and replication [3,4]. It inhibits hydrofolate
reductase, interrupting purine biosynthesis, and it may have
immunosuppressive and anti-inﬂammatory effects. Although the
association of MTX with the development of lymphoma in RA
patients is controversial, more than seventy cases of lymphoma
occurring in patients with RA taking MTX have been reported,
suggesting that in RA, a relationship between MTX and the devel-
opment of lymphoma in some patients appears highly probable.
Salloum et al. [5] reviewed 16 patients with rheumatoid arthritis
whose methotrexate treatment was withdrawn after a diagnosis of
NHL; six (37.5%) had spontaneous complete remission, three (19%)
had partial remission, six (37.5%) had no response and one (6%) had
a minimal response. These data highlight that MTX withdrawal has
resulted in the regression of lymphoma in multiple patients.
Several reports support their data [3,6]; however, no studies
describe an increased risk of developing lymphoma in patients with
RA associated with MTX use in a prospective study. Further studies
are necessary in order to conclude a causal association between
MTX use for RA and lymphoma.
In Sjs, NHL commonly occurs; the prevalence of NHL was found
to be 4.3% in Sjs in a large multicenter European study [7]. Ekstrom
et al. also reported that Sjs was associated with a 6.6-fold increased
risk of NHL [8], and secondary Sjs yielded a higher risk than them and onto the pleura. Formation of lymphoid follicles is scant. The inset is a higher
ohistochemical study revealed aggregates of those cells showed restricted staining for
H. Yasui et al. / Respiratory Medicine Case Reports 15 (2015) 4e66primary form [9]. Furthermore, it has been reported that Sjs
patients are also at a dramatically increased risk of parotid gland
MALT lymphoma [9]. Although pulmonary lymphoma is relatively
rare, it is often reported in patients with Sjs [10,11]. Interestingly,
low-grade NHL accounts for 58e87% of cases of primary pulmonary
lymphoma [12e15], and two-thirds of these cases correspond to
MALT-type NHL [16]. To date, no triggering antigens have been
identiﬁed in the lung, but chronic antigenic stimulation in certain
autoimmune disorders, such as Sjs, are considered to affect the
onset of pulmonary MALT lymphoma [17].
In our case, it is considered that the disease conditions both of
RA with MTX treatment and the presence of Sjs with RA triggered
the development of lymphoma. Importantly, MTX withdrawal has
resulted in the regression of the lymphoma in this patient, sug-
gesting that MTX is associated with MALT lymphoma. Although
MTX is an anchor drug in RA, it is not generally used for primary Sjs.
Hence, there are no data demonstrating the relationship between
MTX and Sjs. We conclude that patients on MTX treatment for RA
should be carefully monitored, especially when concomitant Sjs is
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